

CURRICULUM VITAE

Mary Sorci Thomas PhD

**Professor
Department of Medicine
Division of Medicine Endocrinology**

OFFICE ADDRESS:

8701 Watertown Plank Road

Milwaukee, WI 53226

EDUCATION:

- 1979 BS, Louisiana State University, Baton Rouge, LA
- 1984 PhD, Wake Forest University School of Medicine, Winston-Salem, NC

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

12/1984 - 04/1987 Postdoctoral Fellow, Department of Pharmacological Sciences, State University of New York, Stony Brook, NY

FACULTY APPOINTMENTS:

- 1976 - 1979 Research Technician/Freshman Lab Instructor, Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana, LA
- 1987 - 1988 Instructor, Department of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
- 1988 - 1984 Assistant Professor, Department of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
- 1989 - Present Associate in the Department of Biochemistry, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC
- 1994 - 2002 Associate Professor, Department of Pathology Section of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
- 2002 - Present Professor with Tenure, Department of Pathology Section on Lipid Sciences, Wake Forest University School of Medicine, Winston-Salem, NC
- 2014 - Present Professor with Tenure, Department of Medicine, Division of Endocrinology, Metabolism and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, WI
- 2014 - Present Adjunct Investigator, Blood Research Institute, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:

- 2002 - 2007 Reviewer, Pfizer International HDL Awards 2002-2007
- 2019 - Present Associate Director, Cardiovascular Center, Medical College of Wisconsin

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:

- 2019 - Present Associate Program Director, CVC T32 Training Program, Medical College of Wisconsin

RESEARCH ADMINISTRATIVE APPOINTMENTS:

- 1976 - 1979 Research Technician/Freshman Lab Instructor, Department of Chemistry, Louisiana State University, Baton Rouge, LA
- 2014 - 2015 Senior Adjunct Investigator, Versiti Blood Research Institute
- 2014 - 2015 Associate, Pharmacology and Toxicology, Medical College of Wisconsin

AWARDS AND HONORS:

01/1983 - 12/1984 R.J. Reynolds Special Fellow, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC
07/1983 - 07/1984 Recipient, North Carolina Affiliate Pre-doctoral, Grant-in-Aid, American Heart Association
05/1984 Recipient, Sigma Xi Graduate Research Award in Biomedical Research
12/1984 - 12/1986 Recipient, National Research Service Award Postdoctoral Fellowship, National Institutes of Health
11/1991 Finalist, Louis N. Katz Basic Science Research Prize for Young Investigators, American Heart Association
07/1994 - 06/1999 Established Investigator, American Heart Association
04/06/2002 Recipient, Second Annual Women's Mentoring Award, American Heart Association, The Women's Leadership Committee
06/22/2002 Elected Co-Chair for 2004 and Chair for 2006 Gordon Conference on Lipoprotein Metabolism, Conference on Lipoprotein Metabolism
11/19/2002 Special Recognition Award, Arteriosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association, Chicago, IL
09/2004 - 2011 Kern Aspen Lipid Conference Board
08/22/2010 - Present Chair , Kern Aspen Lipid Meeting
03/09/2015 - Present Texas A&M Keynote Speaker for the Nutritional Graduate Student Association Symposium
12/21/2016 - Present External Advisory Board Columbia University T32 Training Grant

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

American Association for the Advancement of Science
Fellow of the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association
New York Academy of Science
American Society for Biochemistry and Molecular Biology
Society of Sigma Xi
Iota Sigma Pi

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Journal Review
1998 - 2010 Journal of Lipid Research
2008 - Present Arteriosclerosis, Thrombosis, and Vascular Biology
2013 - Present Journal of Lipid Research
PLoS ONE
Atherosclerosis
Circulation Research
Atherosclerosis, Thrombosis, and Vascular Biology
Journal of Biological Chemistry
American Journal of Pathology
Circulation
Nature
Journal Clinical Investigation
Protein Sciences
Biochimica et Biophysica Acta
Biochemistry
Ad-Hoc Reviewer
1992 - 1994 NIH, NHLBI, Metabolism Study Section
1992 - 1994 Special Emphasis Panel on the use of Transgenic Animals in Biomedical Research
1999 NIH, NIA, Program Project Review Committee
2000 - Present NIH, NHLBI, Program Project Review Committee
2003 NIH, NHLBI, Metabolism Study Section
2004 - 2005 NIH, NHLBI, Integrated Nutrition and Metabolic Pathways Study Section,
2004 - 2008 NIH, NHLBI, Atherosclerosis, Inflammation and Cardiovascular Science Study Section
2013 - Present NIH, NHLBI, Vascular Cell and Molecular Biology (VCMB) Study Section

2013 - 2014 NIH, NHLBI, Atherosclerosis, Inflammation and Cardiovascular Systems (AICS) Study
Section
2014 - Present NIH NHLBI Program Project Review Committee

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

1989 - 1992 Research Review Subcommittee, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate
1991 - 2012 Interviewer, Wake Forest University Medical School Admissions, Wake Forest University Medical School
1991 - 1992 Treasurer, Society of Sigma Xi Wake Forest University Chapter, Wake Forest University Graduate School
1992 - 1995 Member, Standing Committee on Nutrition, National American Heart Association
1992 - 1995 Member, Wake Forest University Intramural Research Support Committee, Wake Forest University Graduate School
1992 - 1993 Vice President, Society of Sigma Xi Wake Forest University Chapter, Wake Forest University Graduate School
1992 - 1995 Abstract Grading Consultant, Abstract Grading Consultant, National American Heart Association Scientific Meetings Categories on Arteriosclerosis
1992 - 1995 Board of Directors, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate
1992 - 1995 Research Committee, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate
1992 - 1999 Co-Chairman of High School Student Research Program, AHA N.C. Affiliate, American Heart Association, North Carolina Affiliate
1992 Co-chair, Scientific Session on "Apoprotein Gene Expression", 65th Scientific Session National American Heart Association Meeting
1993 - 1995 Abstract Grading Consultant, National American Heart Association Scientific Meetings Categories on Nutrition
1993 - 1995 Transgenic Mouse Facility Planning Committee, Wake Forest University Graduate School
1993 - 1994 President, Society of Sigma Xi Wake Forest University Chapter, Wake Forest University Graduate School
1993 - 1995 Member, Credentials Committee, National Heart Association
1994 - 1997 Dean's Advisory Committee, Wake Forest University Medical School
1994 - 1998 Executive Committee, Council on Arteriosclerosis, AHA
1994 - 2000 Graduate Council Representative, Wake Forest University, Wake Forest University Graduate School
1994 Administrative Infrastructure Review Working Group, Wake Forest University Graduate School
1994 - 1998 Chair, Women and Minorities Leadership Committee, American Heart Association, Council on Arteriosclerosis
1996 - 2000 Member, Program Project Review Committee, NIH, NHLBI
1997 Co-Chair, Scientific Session on "HDL Metabolism and Gender", 70th Scientific Sessions of the National American Heart Association Meeting, Orlando Florida, 1997
1997 - 2014 Seminar Director, Molecular and Cellular Pathobiology Program, Wake Forest University Graduate School
09/10/1998 - 09/13/1998 Co-Chair, Workshop on "HDL/ApoA-I Structure:Function", th Annual Southeast Lipid Conference, Lake Lanier, GA
1998 - 2005 Committee on Wake Forest University Medical School Admissions, Wake Forest University Medical School
1998 Co-Chair, Scientific Session on "HDL Structure:Function", 71st Scientific Sessions, American Heart Association Meeting, Dallas, Texas
1998 Panelist, 2nd Annual Forum on Graduate Education 1998, "Mentoring, Trends and Models", sponsored by the Graduate School of Arts and Sciences, Wake Forest University, Wake Forest University Graduate School
09/09/1999 - 09/12/1999 Co-Chair, Session on Lipoprotein Biosynthesis and Metabolism I, 8th Southeastern Lipid Conference, Lake Lanier, GA
1999 Co-Chair, Scientific Session on "Lipoprotein Metabolism and Atherosclerosis in Transgenic and Knockout Models", 72rd Scientific Session, American Heart Association Meeting, Atlanta, Georgia
1999 - 2005 Wake Forest University School of Medicine Scholarship Selection Committee, Wake Forest University Medical School

05/20/2000 - 05/22/2000 Co-Chair, Session on "Role of HDL in Atherosclerosis", 1st Conference on Atherosclerosis, Thrombosis and Vascular Biology 2000, Denver, CO

2000 - 2004 Graduate Council Representative, Wake Forest University Senate, Wake Forest University Graduate School

2000 Co-Chair, Session on "Lipoprotein Metabolism and Atherosclerosis in Transgenic and Knockout Animal Models", 73rd Scientific Session, American Heart Association Meeting, New Orleans, Louisiana, 2000

2001 - 2005 Advisory Board, Journal of Lipid Research

2001 - 2012 Wake Forest University School of Medicine MD./PhD Applicant Interview Committee, Wake Forest University Medical School

10/03/2002 - 10/06/2002 Chair, Session on Lipoprotein Metabolism, 11th Southeastern Lipid Conference, Callaway Gardens, GA

09/18/2003 - 09/21/2003 Conference Co-Chair, 12th Southeastern Lipid Conference, Callaway Gardens, GA

09/2003 External Advisor, Program Project, University of California - Davis

2003 Panelist, Annual Forum on Graduate Education 2003, "Mentoring, What Every Graduate Student Wants to Know" sponsored by the Graduate School of Arts and Sciences, Wake Forest University, Wake Forest University Graduate School

05/04/2004 - 05/08/2004 Judge, Irvine H. Page Young Investigator Award for the Council on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association, at the Conference on Atherosclerosis, Thrombosis and Vascular Biology, San Francisco, California

09/01/2004 - 09/01/2011 Kern Aspen Lipid Conference Board

09/23/2004 - 09/25/2004 Conference Chair, 13th Southeastern Lipid Conference, Callaway Gardens, GA

2004 Co-Chair, Session on "Novel Anti-Atherogenic Strategies", 74th Scientific Session, American Heart Association Meeting, New Orleans, Louisiana, 2004

2004 - 2009 Member, Faculty Development and Career Committee, Wake Forest University Medical School

2004 Co-Chair, Gordon Conference on Lipoprotein Metabolism

2004 Department of Ob/Gyn Chair Search Committee, Wake Forest University Medical School

2005 - 2019 Board Member, Kern Vail Lipid

2005 Co-Chair, Session on "Cholesterol Trafficking and Homeostasis", 75th Scientific Session, American Heart Association Meeting, Dallas, Texas, 2005

2006 Chair, Gordon Conference on Lipoprotein Metabolism

2007 Translational Science Institute Symposium on Inflammation Planning Committee, Wake Forest University Medical School

2007 - 2009 Member, National Heart Association, Arteriosclerosis, Thrombosis and Vascular Biology Annual Spring Meeting Program Committee

2007 Abstract Grading Consultant, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Chicago IL 2007

2007 - 2009 Dean's Advisory Committee, Wake Forest University Medical School

2007 - 2009 Basic Science Representative for 2 terms, Faculty Executive Committee, Wake Forest University Medical School

2008 - 2012 Charter Member, NIH, NHLBI, Atherosclerosis, Inflammation and Cardiovascular Science Study Section

2008 Co-Chair, Plenary Session I. Lipid Metabolism and Mechanisms of Atherosclerosis Development, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Atlanta GA. 2008

2008 Abstract Grading Consultant, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Atlanta GA. 2008

2009 - 2011 Re-elected as the Basic Science Representative, Faculty Executive Committee, Wake Forest University Medical School

2009 Abstract Grading Consultant, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Washington DC. 2009

2009 - 2011 Dean's Advisory Committee, Wake Forest University Medical School

2009 - 2011 Member, Faculty Development and Advancement Committee, Wake Forest University Medical School

2009 Co-Chair, Concurrent Session on Lipid Metabolism. National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Washington DC. 2009

08/22/2010 Chair, Kern Aspen Lipid Meeting

2010 - 2011 Faculty Executive Committee, Wake Forest University Medical School
 2011 Co-Chair, Session on Apoprotein Structure and Function. National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Meeting. Chicago IL. 2011
 2012 - Present Leadership Committee, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Council
 2012 - Present Nominating Committee, National American Heart Association, Atherosclerosis, Thrombosis, and Vascular Biology Council
 2014 Member, Nominating Committee, Wake Forest University Medical School
 2015 - Present Board of Directors, Lipid Research, Inc (LRI)
 2015 - Present Standing Review Panel, American Heart Association Cardiovascular Genome-Phenome Study (CVGPS)
 2016 - 2022 Co-Chair, Chair, Atherosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association
 2016 National Heart Lung and Blood Institute Board of Scientific Counselors, NHLBI Division of Intramural Research DIR Site Visit Review 2016
 2016 Board of Scientific Counselors, National Heart Lung and Blood Institute Board of Scientific Counselors, NHLBI Division of Intramural Research DIR Site Visit Review 2016

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Non-Peer Review

Title: "HDL ApoA-I Processing and Biogenesis During ABCA1 Mediated Cholesterol Efflux"
 Source: 1R01HL119847-01 National Institutes of Health/NHLBI
 Role & Effort: Principle Investigator
 PI: Principle Investigator (Sorci-Thomas)
 Dates: 03/31/2015 - 04/01/2019

Prior

Peer Review

Title: "Apolipoprotein E and A-I Lipid Complex Structures"
 Source: National Institutes of Health/NHLBI
 NHLBI RO1 HL 64963
 Role & Effort: Participating Investigator: (Sorci-Thomas)
 PI: Weisgraber
 Dates: 04/01/2000 - 10/31/2003

Title: "Biophysics of HDL Dysfunction"
 Source: 1R01HL112270-01A1 National Institutes of Health/NHLBI
 PI: Pritchard, KA and Sorci-Thomas, Mary G
 Dates: 07/16/2012 - 06/30/2016

Title: "T Regulatory Lymphocytes, HDL Function, and Atherosclerosis"
 Source: 1R01HL112276-01A1 National Institutes of Health/NHLBI
 PI: Multiple Principle Investigator (Hedrick, Catherine (contact); Sorci-Thomas, Mary G)

Dates: 06/01/2013 - 04/30/2017

Non-Peer Review

Title: "Atherosclerosis and Peripheral Apoprotein E Synthesis"
Source: National Institutes of Health/NHLBI
R29 HL41916 (Sorci-Thomas)
PI: Principal Investigator (Sorci-Thomas)
Dates: 12/01/1988 - 11/30/1986

Title: Program Project Entitled: "Lipoprotein Metabolism in Atherosclerosis" Project Entitled: "Structure:Function Relationships of ApoA-I"
Source: National Institutes of Health/NHLBI
PO1 HL049373-20 (LL Rudel)
Role & Effort: Project 4 Project Leader: Sorci-Thomas
Dates: 03/31/1993 - 06/30/2013

Title: "Species-Specific Regulation of the Apolipoprotein A-I Gene"
Source: American Heart Association NC Affiliate
PI: Principal Investigator: Sorci-Thomas
Dates: 06/01/1994 - 05/31/1998

Title: "Structure:Function Relationships of Apolipoprotein A-1"
Source: American Heart Association Established Investigator Award 94001570
PI: Principal Investigator (Sorci-Thomas)
Dates: 07/01/1994 - 06/30/1999

Title: "Inflammation and Inhibition of Cholesterol Transport"
Source: National Institutes of Health/NHLBI
RO1 HL064163-12
Role & Effort: Principal Investigator (Sorci-Thomas)
Dates: 12/01/1999 - 12/31/2014

Source: Tobacco-Related Disease Research Program, Biomedical Sciences Grant Reviewer
Role & Effort: Grant reviewer
Dates: 2003 - 2007

Title: "Lipidation state and the 3-dimensional conformation of ApoA-I"
Source: Pfizer International HDL Research Award
PI: Participating Investigator: (Sorci-Thomas)
Dates: 10/01/2005 - 09/30/2007

Source: Cardiovascular Disease Study Section for Tobacco-Related Disease Research

	Program, Biomedical Sciences, Oakland, CA 2008
Role & Effort:	Chair
Dates:	2008

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

- Presentation of: Gene Regulation of Apolipoprotein AI: Identification of Species-Specific Cis-Acting Elements, Department of Medicine and the Robarts Research Institute, University of Western Ontario, London, Canada, 12/10/1992
- Presentation of: Gene Regulation of Apolipoprotein AI: Identification of Species Specific Cis-Acting Elements, University of Toronto, St. Michael's Hospital, Lipid Research Group, Toronto, Canada, 12/11/1992
- Presentation of: LCAT Activation and the Interaction Between Adjacent α -helical Domains in Apolipoprotein A-I, Department of Biochemistry, The University of Queensland, Brisbane, Australia, 10/27/1994
- Presentation of: Apo A-I Cis-Acting Elements Responsible for High Level Expression, Allelix Biopharmaceuticals, Inc, Mississauga, Ontario, Canada, 10/22/1996
- Presentation of: Alteration in Apolipoprotein A-I 22-mer Repeat Order Results in a Decrease in Lecithin:Cholesterol Acyltransferase Reactivity, Lipid and Lipoprotein Research Group, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada, 04/04/1997
- Presentation of "Alternate conformations of lipid-bound apoA-I delineated by cross-link analysis and mass spectrometry", 2004 HDL Workshop, Heraklion, Crete, Greece, 09/03/2004
- Presentation of "Three Dimensional Information on the Lipid-Bound Conformation of ApoA-I", 2006 XIV International Symposium on Atherosclerosis-Satellite Symposium: HDL From Basic Science to Therapeutic Applications, Parma, Italy, 06/23/2006 - 06/24/2006
- Presentation of "Conformational adaptation of apolipoprotein A-I to discretely sized phospholipid complexes", The International Atherosclerosis Society Workshop on HDL Structure, Protective Functions and Therapeutic Applications, Santorini, Greece, 10/09/2007 - 10/12/2007
- Presentation of "Regulatory T Cells, Autoimmunity and Cholesterol Homeostasis", 6th International Atherosclerosis Society Sponsored Workshop on HDL, Whistler, BC Canada, 05/19/2010
- Presentation of "PCPE2- A Novel Determinant in HDL Function", HDL ApoA-I Structure Workshop following ATVB Conference, Toronto, Canada, 05/03/2014

National

- Presentation of: Cholesteryl esters do not remain intact in the circulation, 57th Annual Scientific Sessions of the American Heart Association, Miami, Florida, 11/11/1984 - Present
- Presentation of: Regulation of apolipoprotein AI mRNA levels by dietary fat and cholesterol, 58th Annual Scientific Sessions of the American Heart Association, Washington, DC, 11/12/1985
- Presentation of: Transcription of the monkey apoE gene, 58th Annual Scientific Sessions of the American Heart Association, Washington, DC, 11/12/1985
- Presentation of: Effects of dietary fat and cholesterol on apoprotein A-I mRNA abundance in nonhuman primates, Research Institute, Palo Alto Medical Foundation, Palo Alto, CA, 09/05/1986
- Presentation of: Cholesteryl esters do not remain intact in the circulation, University of Washington, Department of Medicine, Division of Metabolism, Seattle, Washington, 09/08/1986
- Presentation of: Effects of dietary fat and cholesterol on apoprotein A-I mRNA abundance in nonhuman primates, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 11/03/1986
- Presentation of: Peripheral apolipoprotein AI mRNA abundance in the nonhuman primate, 59th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, 11/19/1986
- Presentation of: Effects of dietary fat and cholesterol on the expression of genes encoding apoA-I, A-II, B and E in the liver and small intestine of nonhuman primates, NIH Conference on the Effects of Diet Composition on Apolipoprotein Metabolism, Phoenix, Arizona, 02/19/1987
- Poster presentation of: Liver low density lipoprotein receptor mRNA levels in cholesterol-fed nonhuman primates, 60th Annual Scientific Sessions of the American Heart Association, Anaheim, California, 11/17/1987
- Poster presentation of: Regulation of apolipoprotein gene expression, Gordon Research Conference, Lipid

Metabolism, Meriden, NH, 06/21/1989

Presentation of: Regulation of apolipoprotein A-I gene expression, Louisiana State University Medical Center
Department of Physiology, New Orleans, Louisiana, 10/10/1989

Presentation of " Transcriptional regulation of apolipoprotein A-I gene in nonhuman primates with low and
high susceptibilities to diet induced atherosclerosis", Warner-Lambert Parke-Davis, Ann Arbor, MI,
11/02/1989

Poster presentation of: Transcriptional regulation of apolipoprotein A-I gene in nonhuman primates with low
and high susceptibilities to diet induced atherosclerosis, 62nd Annual Scientific Sessions of the
American Heart Association, New Orleans, Louisiana, 11/18/1989

Presentation of: Nutritional regulation of apolipoprotein and low density lipoprotein gene expression, Pfizer
Central Research, Department of Metabolic Diseases, Groton, Connecticut, 02/12/1990

Presentation of: Regulation of apolipoprotein gene expression in nonhuman primates fed dietary fat and
cholesterol, Division of Cardiovascular Research Schering-Plough, Bloomfield, N.J, 12/16/1990 -
12/16/1990

Presentation of: Genetic regulation of ApoA-I, Columbia University, Department of Medicine, New York,
New York, 12/17/1990

Presentation of: Transcriptional Regulation of Apolipoprotein A-I, University Southern California,
Department of Pharmacology and Toxicology, Los Angeles, CA, 06/10/1991

Presentation of: Transcriptional regulation of the apolipoprotein A-I gene, 64th Annual Scientific Sessions of
the American Heart Association, Anaheim, California, 11/11/1991

Poster presentation of: Species-specific regulation of the apoA-I gene, University of California at San Diego
Asilomar Conference, Molecular and Cellular Biology of the Cardiac Myocyte, Pacific Grove,
California, 11/18/1991

Poster presentation of: Structure:function relationships of ApoA-I, hird International Conference on HDL and
Atherosclerosis, San Antonio, TX, 03/05/1992

Poster presentation of: Structure:function relationships of ApoA-I, Gordon Research Conference, Lipid
Metabolism, Meriden, N.H, 06/18/1992

Presentation of: Transcriptional Regulation of Apolipoprotein A-I: Cis-Element Crosstalk, Oncogene
Sciences, Inc., Long Island, New York, 07/08/1992

Presentation of: LCAT activation and amphipathic -helical domains of apoA-I, Department of
Medicine/Cardiology at the University of California at Los Angeles, Los Angeles, CA, 08/03/1992

Presentation of: Transcriptional Regulation of the ApoA-I Gene: Cross Talk between Distinct Regions of the
Promoter, Division of Liver Biology at Monsanto/Searle Corporate Research, St. Louis, Missouri,,
09/15/1992

Presentation of: Regulation of ApoA-I Expression: Heredity vs. Diet, Division of Cardiovascular Research at
Washington University School of Medicine, St Louis, Missouri, 09/16/1992

Presentation of: Structure:function Relationships of ApoA-I, Lipid Investigator Research Conference at
Merck, Human Health Division, Rahway, New Jersey, 10/24/1992

Presentation of: ApoA-I Regulations: Structural Determinants and Atherogenesis, Cardiovascular Central
Nervous System Research Section of American Cyanamid Company, Lederle Laboratories, Pearl
River, New York, 01/20/1993

Presentation of: ApoA-I Regulation:Structural Determinants and Atherogenesis, Department of Biochemistry,
East Carolina School of Medicine, Greenville, NC, 02/15/1993

Presentation of: Regulation of Apolipoprotein Gene Expression in Nonhuman Primates and Model Systems,
The University of North Carolina at Greensboro, School of Human Environmental Sciences, The
University of North Carolina at Greensboro, School of Human Environmental Sciences Department of
Food, Nutrition and Food Service Management, 03/15/1993

Presentation of: Site-directed Mutagenesis in Structure:Function Studies, Southeastern Lipoprotein
Conference, Callaway Gardens, Georgia, 04/16/1993

Presentation of: Apolipoprotein A-I Domains Involved in Lecithin:Cholesterol Acyltransferase Activation.
Structure:Function Relationships., Department of Biochemistry, University of Illinois, Urbana, Illinois,
09/24/1993

Presentation of: Species-Specific Expression of the ApoA-I Gene is Regulated by Point Mutations in the
Promoter Region, American Heart Association Meetings, Atlanta, Georgia, 11/08/1993

Poster presentation of: LCAT Activation and the Interaction Between Adjacent alpha-helical Domains in
ApoA-I, Gordon Research Conference on Lipid Metabolism, Meriden, New Hampshire, 06/19/1994 -
06/24/1994

Presentation of: Apolipoprotein A-I Domains Involved in Lecithin:cholesterol Acyltransferase Activation. Structure:Function Relationships, Division of Gerontology/Geriatric Medicine, Dept. of Medicine, University of Alabama School of Medicine, Birmingham, AL, 07/06/1994

Poster Presentation of: The Role of Inter-Molecular α -Helical Interaction in Apolipoprotein A-I Activation of Lecithin:Cholesterol Acyltransferase, American Heart Association 67th Scientific Sessions, Dallas, TX, 11/14/1994

Poster Presentation of: Alteration in Apo A-I 22-mer Repeat Order Reduces its Ability to Activate LCAT, Gordon Research Conference on Lipid Metabolism, Meriden, New Hampshire, 06/19/1996

Poster Presentation of: Alteration in Apo A-I 22-mer Repeat Order Reduces its Ability to Activate LCAT, American Heart Association 69th Scientific Sessions, New Orleans, LA, 11/10/1996 - 11/13/1996

Presentation of: Alteration in ApoA-I 22-mer Repeat Order Reduces its Ability to Activate LCAT, National Heart, Lung, and Blood Institute, DHVD, Bethesda, MD, 12/04/1996

Presentation of: Apo AI Δ 143-164 Transgenic Mice Acquire Severe Hypoalphalipoproteinemia in the Absence of Endogenous Mouse Apo A-I, Southeast Lipid Conference, Lake Lanier Islands Hilton Resort, Georgia, 09/05/1997

Poster Presentation of: Transgenic Model of Severe Hypoalphalipoproteinemia Resulting from the Deletion of a Single 22-mer Repeat within Apo A-I, American Heart Association 70th Scientific Sessions, Orlando, FL, 11/11/1997

Presentation of: Unique Features of the 143-164 Residue Domain of Apo A-I. Studies of LCAT Activation in vitro and in vivo, Workshop on HDL/Apo A-I Structure:Function, 7th Annual Southeast Lipid Conference, Lake Lanier Hilton Resort, Georgia, 09/11/1998

Presentation of: Apolipoprotein A-I Mutation Blocks Pre- β -HDL Particle Formation and Maturation in Transgenic Mice, American Heart Association 71st Scientific Sessions, Dallas, Texas, 11/11/1998

Visiting Professorship, University of Alabama at Birmingham, 04/26/1999 - 04/30/1999

Presentation of: Unique Features of the 143-164 Residue Domain of Apo A-I: Studies of LCAT Activation in vitro and in vivo, Gladstone Institute of Cardiovascular Disease, San Francisco, CA, 05/17/1999

Presentation of: "Apo A-I Mutants and LCAT Activity", 8th Southeastern Lipid Conference, Lake Lanier, Georgia, 09/10/1999

Presentation of: "Apo A-I Mutation Reduces LCAT Catalyzed Plasma Cholesterol Esterification in the Presence of Wild-Type Apo A-I", American Heart Association 72nd Scientific Sessions, Atlanta, Georgia, 11/07/1999

Presentation of "The Effects of Mutant Forms of Apo A-I on HDL Concentration and Risk for Atherosclerosis", Warner-Lambert Parke-Davis, Ann Arbor, MI, 02/10/2000 - 02/11/2000

Keynote address of "The Role of Mutant forms of Apo A-I on HDL Metabolism and Atherosclerosis", First Conference on Atherosclerosis, Thrombosis and Vascular Biology 2000, Denver CO, 05/21/2000

Presentation of: "Effect of Mutant forms of Apo A-I on HDL Metabolism and Atherosclerosis, The Gordon Conference on Lipid Metabolism, Meriden NH, 07/24/2000 - 07/30/2000

Presentation of: "Intravascular Metabolism of HDL and Mutant forms of Apo A-I", Ninth Annual Southeastern Lipid Research Conference, Lake Lanier Islands Hilton Resort, Georgia, 09/08/2000

Presentation of "The Effect of Mutant Forms of Apo A-I on HDL Concentration and Risk for Atherosclerosis", Appalachian State University, Boone, NC, 09/20/2000

Poster presentation of: "Intracellular Quality Control in the Apo A-I Secretory Pathway: Accumulation of Phospholipid and Δ 143 apo A-I Inclusions, American Heart Association 73rd Scientific Sessions, New Orleans, Louisiana, 11/13/2000

Presentation of: "Apo A-I Polymorphisms: Impact on HDL Concentration": Assessing HDL as a Risk Factor in Coronary Heart Disease, A Working Group Meeting Sponsored by Merck HHD, Scottsdale, Arizona, 01/12/2001 - 01/13/2001

Presentation of: "Human Apo A-I Polymorphisms and HDL Metabolism: Association with LCAT Activation by Apo A-I", Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio, 04/05/2001

Presentation of: "Human Apo A-I Polymorphisms and HDL Metabolism", Department of Pathology, University of Chicago, Chicago, Illinois, 04/30/2001

Presentation of: "Human Apo A-I Polymorphisms and their Effects on HDL Metabolism", Department of Nutritional Sciences, University of Kentucky, Lexington, Kentucky, 05/25/2001

Presentation of "Human Apo A-I Polymorphisms and their Effects on HDL Metabolism, Pfizer Research, Ann Arbor, MI, 08/29/2001 - 08/30/2001

Presentation of: "Effects of ApoA-I Mutations on HDL Concentrations : Insights From FRET Studies",

Department of Pathology, University of Chicago, Chicago, Illinois, 07/17/2002

Presentation of “Studies in Mice Lacking Both LDL Receptors and ApoA-I”, 11th South Eastern Lipoprotein Research Conference, Callaway Gardens, Georgia, 10/04/2002

Presentation of “HDL Apo A-I Mutations and their Effects on Cholesterol Homeostasis”, 4th Annual International Conference on HDL Cholesterol; Metabolic Pathways and Drug Development, Boston, MA, 03/03/2003 - 03/05/2003

Presentation of “Inhibition of Reverse Cholesterol Transport in LDLr^{-/-}, ApoA-I^{-/-} Mice Leads to Inflammation and Atherosclerosis, Children’s Hospital of Oakland Research Institute, Oakland, CA, 05/05/2004

Presentation of “Inhibition of Reverse Cholesterol Transport in LDLr^{-/-}, ApoA-I^{-/-} Mice Leads to Inflammation and Atherosclerosis”, 2004 Gordon Conference on Lipoprotein Metabolism, Meriden, NH, 06/14/2004

Presentation of “Structural studies of lipid-bound apoA-I using chemical cross-linking and mass spectrometry”, Vanderbilt University, Nashville, TN, 09/14/2004

Presentation of “Inhibition of reverse cholesterol transport in LDLr^{-/-}, ApoA-I^{-/-} mice leads to inflammation and atherosclerosis”, 2005 Deuel Conference on Lipids, Dana Point, CA, 03/01/2005 - 03/04/2005

Presentation of “Linking the tertiary structure of apoA-I to its anti-atherogenic role in HDL metabolism”, 2005 Aspen Kern Lipid Conference, Aspen, CO, 08/20/2005 - 08/23/2005

Presentation of “3-dimensional information on the lipid-bound conformation of apoA-I”, 005 David L. Williams Memorial Symposium on “Molecular Mechanisms Regarding Cholesterol Metabolism in Atherosclerosis”, Stony Brook, NY, 10/28/2005

Presentation of “The role of HDL ApoA-I in Inflammation and Cholesterol Homeostasis”, 2006 Winter Gordon Conference on Oxygen Radicals, Ventura Beach, CA, 02/07/2006

Presentation of “Linking the tertiary structure of apoA-I to its anti-atherogenic role in HDL metabolism”, Boston University, Department of Pharmacology and Biophysics, Boston, MA, 05/08/2006 - 05/09/2006

Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly and function”, Department of Medicine at the University of Washington, Seattle, WA, 12/12/2007 - 12/14/2007

Presentation of “Collaborations Present and Future: Mouse Models of Atherosclerosis”, First Annual Hypertension and Vascular Research Center Global Retreat, Wake Forest University Health Sciences, 01/10/2008

Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly and function”, Robert M. Berne Cardiovascular Research Center at the University of Virginia, Charlottesville, VA, 02/06/2008

Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly, maturation and function”, 2008 Gordon Conference on Lipoprotein Metabolism, Waterville, NH, 06/22/2008

Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, NIH NHLBI Conference on HDL Structure and Function, Washington, DC, 04/27/2009

Presentation of “Three dimensional models of high density lipoprotein apoA-I: Implications for its assembly and lipidation”, Spring HDL ApoA-I Structure Workshop, Washington, DC, 05/02/2009

Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, Medical University of South Carolina, Charleston, SC, 05/14/2009

Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, Columbia University, New York, NY, 05/27/2009

Presentation of “ApoA-I Structure and Function: Regulation of Cholesterol Homeostasis and Inflammation”, SUNY Downstate Medical Center, Brooklyn, NY, 05/28/2009

Presentation of “HDL, ApoA-I Its Role in Autoimmunity and Cholesterol Homeostasis”, University of Kentucky, Lexington, KY, 12/17/2009

Presentation of “Autoimmunity and Cholesterol Homeostasis”, Gordon Research Conferences on Lipoprotein Metabolism, Waterville Valley, NH, 06/22/2010

Presentation of “HDL, ApoA-I and its role in Regulating Autoimmunity”, Kern Aspen Lipid Conference, Aspen, Colorado, 08/22/2010

Presentation of “HDL ApoA-I What Makes It Act As The “Good Cholesterol?”, Rutgers University, New Brunswick, New Jersey, 09/27/2010

Presentation of “Why is HDL ApoA-I Anti-Atherogenic and Anti-Inflammatory? It’s All About the

Cholesterol!”, 75th New York Lipid Club Meeting, Rockefeller University, New York, New York, 09/28/2010

Presentation of “HDL ApoA-I; What Makes It Protective or the “Good Cholesterol?”, Southeast Lipid Research Conference, Pine Mountain, Georgia, 10/09/2010

Presentation of “Biogenesis of Nascent HDL”, 10th Arteriosclerosis Thrombosis and Vascular Biology Meeting, Chicago, IL, 04/28/2011

Presentation of “HDL ApoA-I and Its Role in Autoimmunity and Atherosclerosis”, HDL ApoA-I Structure Workshop, Chicago, IL, 05/01/2011

Presentation of “HDL ApoA-I and Autoimmunity”, Gordon Conference on Atherosclerosis, Newport, Rhode Island, 06/22/2011

Presentation of “High Density Lipoproteins, Autoimmunity and Atherosclerosis”, La Jolla Institute for Allergy and Inflammation, La Jolla, CA, 02/22/2012

Presentation of “HDL ApoA-I and Its Role in Autoimmunity and Atherosclerosis”, Keystone Symposium on the Molecular Basis of Inflammation and Atherosclerosis, Big Sky, MT, 03/26/2012

Poster Presentation of: “3-Dimensional Conformation of HDL ApoA-I Generated via ABCA1“, American Heart Association; Atherosclerosis, Thrombosis and Vascular Biology Meeting (ATVB), Chicago, IL, 04/20/2012

Presentation of “Cholesterol Efflux, Microdomains and the Role of Nascent HDL Biogenesis in Chronic Inflammation and Atherosclerosis”, HDLApoA-I Structure Workshop following ATVB Conference, Chicago, IL, 04/21/2012

Presentations of “Cholesterol Efflux, Microdomains and the Role of Nascent HDL Biogenesis” and Role of ApoA-I in Chronic Inflammation and Atherosclerosis”, Department of Medicine at the University of Washington, Seattle, WA, 05/23/2012 - 05/24/2012

Presentation of “Cholesterol Efflux, Microdomains and the Role of Nascent HDL Biogenesis in Atherosclerosis”, Gordon Research Conference on Lipoprotein Metabolism, Waterville Valley, NH, 06/20/2012

Presentation of: “HDL, Autoimmunity and Atherosclerosis”, Southeast Lipid Research Conference, Pine Mountain, Georgia, 09/26/2012 - 09/29/2012

Presentation of: HDL, Atherosclerosis and Autoimmunity”, American Heart Association Meetings, Los Angeles, CA, 11/02/2012 - 11/07/2012

Poster Presentation of: “Lipid Acquisition and a Novel Role for PCPE2“, American Heart Association; Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference, Orlando, FL, 04/30/2013 - 05/04/2013

Presentation of “PCPE2- A Novel Determinant in HDL Biogenesis and Metabolism”, HDL ApoA-I Structure Workshop following ATVB Conference, Orlando, FL, 05/03/2013

Presentation of “PCPE2- A Novel Determinant in HDL Biogenesis and Metabolism”, LSU Pennington Biomedical Research Center, Baton Rouge, LA, 09/09/2013

Presentation of “PCPE2, Atherosclerosis and HDL Function”, The Medical College of Wisconsin, Milwaukee, WI, 02/03/2014

Presentation of “PCPE2, SR-BI and HDL Function”, Department of Cellular Biology and Anatomy LSU Health Sciences Shreveport, Shreveport, LA, 10/05/2014 - 10/07/2014

Keynote Speaker, Nutritional Graduate Student Association Symposium, Texas A&M University, 03/09/2015

Presentation of “PCPE2, SR-BI and HDL Function”, New York University Langone Medical Center Retreat, Putnam Valley, NY, 06/20/2015

Presentation of “PCPE2, SR-BI and HDL Function”, Gordon Research Conference on Atherosclerosis, Sundry River, ME, 06/22/2015

Presentation of “PCPE2, SR-BI and Reverse Cholesterol Transport”, Texas A&M, Department of Nutrition Science, College Station, TX, 10/11/2015

Presentation of “Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) Deficiency Profoundly Affects Adipose Distribution in Mice and Humans Linking HDL Metabolism to Adipocyte Biology”, 15th annual ATVB Conference, Nashville, TN, 05/06/2016

Local

SR-BI and PCPE2 Modulate Lipid Trafficking in Adipocytes, Endocrine Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, 02/01/2018

Current Concepts in Cardiovascular Biology, Current Concepts in Cardiovascular Biology Course, Medical College of Wisconsin, Milwaukee, Wisconsin, 08/17/2021

COMMITTEE SERVICE:

Medical College of Wisconsin

- 2015 Chair, Mentoring Committee for Srividya Kidambi, MD, Medical College of Wisconsin
- 2015 Chair, Mentoring Committee for Michael Yeboah, MD Ph.D, Medical College of Wisconsin
- 2016 Associate Program Director, Cardiovascular Center T32 “Training in Signature Transdisciplinary Cardiovascular Sciences”, Medical College of Wisconsin
- 2016 Cardiovascular Center Core Equipment Advisory Committee, Medical College of Wisconsin

EXTRAMURAL TEACHING:

Medical Student Education

- 1987 - 1988 Wake Forest University School of Medicine, Winston-Salem, NC, Instructor, Department of Comparative Medicine
- 1991 - 1998 Wake Forest University School of Medicine, Small group discussion leader for 1) Lipoprotein/ Atherosclerosis Section and 2) Oncogenes/Cancer for the General Biochemistry Unit I

Graduate Student Education

- 1987 - 2014 Wake Forest University School of Medicine, Each year I have directed the research of one or two graduate students who have rotated through my laboratory.
- 1988 - 2014 Wake Forest University School of Medicine, 1-Semester Graduate Level Course in Disturbances in Lipoprotein Metabolism-COMD 709. My contribution to this group taught course is 2-3 1-hour lectures.
- 1988 - 2014 Wake Forest University School of Medicine, 2-Semester Graduate Level Course in Molecular Biology - Molecular Genetics 731 and 732. My contribution to this group taught course 7-8 1.5 hour lectures.
- 1988 - 2014 Wake Forest University School of Medicine, 1 Semester Graduate Level Course in Pathobiology of Atherosclerosis-PATH 417. My contribution to this group taught course is 2-3 1 hr lectures

Resident and Fellow Education

- 1993 - 1996 Wake Forest University School of Medicine, Served on an NIH Gerontology Fellowship Training Grant Oversight Committee. This training grant was directed by Dr. Walter Ettinger, Professor of Medicine. Our committee met quarterly to evaluate the research progress of each of the 7 fellows supported by the grant.

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS

MENTORED:

Medical Students

- 1979 - 1982, Tutored medical students in General Biochemistry and lead group discussions on specific areas such as Acid:Base Chemistry and Enzymology. Graduate Teaching Assistant in Biochemistry., Wake Forest University School of Medicine, Department of Biochemistry
- 1988 - 1990 Shari Orlieck, M.D. - Pediatrics, Mentor/Advisor, Wake Forest University School of Medicine
- 1999 - 2001, Faculty Tutor, Wake Forest University School of Medicine, Phase IIC and IB of the Basic and Clinical Science Problems Course WFUBMC
- 2000 - 2002 Diana Rubin (MSIV), Medical Student Mentorship Program, Medical Student Mentorship Program
- 2011 Candice Brown, Ph.D - Internal Medicine, Mentor/Advisor, Wake Forest University School of Medicine
- Susan Brock, Mentor for an Experimental Mentoring Program, Salem College in Winston-Salem, NC

Graduate Students

- 1990, Fall of 1990, I planned and organized a Tutorial Program from the graduate students at WFUBMC. Dr. Lawrence Chan, from Baylor University, tutored our students on the “Molecular

Genetics of Apolipoproteins".
2003, Participated as one of 5 panelist in a 2003 Graduate Forum on Mentoring Graduate Students.
Panelist represented different areas of career s after obtaining a Ph.D. in Biomedical Studies.

Postdoctoral Researchers

1988 - 1990 Vivek K. Varma, M.D, Mentor/Advisor
1993 - 1996 Melanie T. Paff, Ph.D., Mentor/Advisor, Wake Forest University School of Medicine
1998 - 2002 Hui-hua Li, M.D., Ph.D., Mentor/Advisor, Wake Forest University School of Medicine
2000 - 2010 Shaila Bhat, Ph.D., Mentor/Advisor
2003 - 2007 Mannish Bharadwaj, Ph.D., Mentor/Advisor, Wake Forest University School of Medicine
2005 - 2006 Lijun Tang, MD. Ph.D., Mentor/Advisor
2010 - 2014 Kristina Brzoza-Lewis, Ph.D., Mentor/Advisor, Wake Forest University School of Medicine
2012 - 2014 Chris Blesso, Ph.D., Mentor/Advisor, Wake Forest University School of Medicine

Clinical/Research Fellows

1992 - 1993, Research, supported by an American Heart Association. Mr. Lee took a 1 yr leave from medical school to do research in my laboratory.
2005 - 2011 John Owen, Ph.D., Research Associate Directed, Wake Forest University School of Medicine

ACTIVE GRANTS:

07/16/2012 - 06/30/2016 1R01HL112270-01A1 National Institutes of Health/NHLBI Multiple Principle Investigator (Pritchard, KA (contact); Sorci-Thomas, Mary G) Project Entitled: "Biophysics of HDL Dysfunction" This project will investigate the mechanism by which chronic states of oxidative stress and inflammation impair HDL function.
06/01/2013 - 04/30/2017 1R01HL112276-01A1 National Institutes of Health/NHLBI Multiple Principle Investigator (Hedrick, Catherine (contact); Sorci-Thomas, Mary G) Project Entitled: "T Regulatory Lymphocytes, HDL Function, and Atherosclerosis" This project will examine T regulatory lymphocytes (Treg) and the role of high-density lipoprotein (HDL) transport of sphingosine-1-phosphate (S1P) on their modulation during the process of atherogenesis.
07/12/2013 - 06/30/2018 1R01 HL118206-01 National Institutes of Health/NHLBI Principle Investigator (Randolph, G) Participating Investigator (Sorci-Thomas and Thomas) Project Entitled: "VEGF-C/VEGFR3 and Lymphatic Transport of Cholesterol from Atherosclerotic Plaque"

PENDING GRANTS:

1R01HL119847-01 National Institutes of Health/NHLBI Principle Investigator (Sorci-Thomas) Project Entitled: "HDL ApoA-I Processing and Biogenesis During ABCA1 Mediated Cholesterol Efflux" This project will investigate and define the novel role for Procollagen C Proteinase Enhancer 2 (PCPE2) in the formation and function of HDL as it relates to the progression of atherosclerosis.

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Sorci-Thomas M, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL. Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apoA-I and high density lipoprotein differences between two nonhuman primate species with high and low susceptibilities to diet-induced hypercholesterolemia. *J Biol Chem.* 1988 Apr 15;263(11):5183-9.
2. Sorci-Thomas M, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. *J Lipid Res.* 1989 Sep;30(9):1397-403.
3. Sorci-Thomas M, Wilson MD, Johnson FL, Williams DL, Rudel LL. Studies on the expression of genes encoding apolipoproteins B100 and B48 and the low density lipoprotein receptor in nonhuman primates. Comparison of dietary fat and cholesterol. *J Biol Chem.* 1989 May 25;264(15):9039-45.
4. Sorci-Thomas M, Babiak J, Rudel LL. Lecithin-cholesterol acyltransferase (LCAT) catalyzes transacylation of intact cholesteryl esters. Evidence for the partial reversal of the forward LCAT reaction. *J Biol Chem.* 1990 Feb 15;265(5):2665-70.
5. Sorci-Thomas M, Kearns MW. Transcriptional regulation of the apolipoprotein A-I gene. Species-specific

- expression correlates with rates of gene transcription. *J Biol Chem.* 1991 Sep 25;266(27):18045-50.
6. Sorci-Thomas M, Hendricks CL, Kearns MW. HepG2 cell LDL receptor activity and the accumulation of apolipoprotein B and E in response to docosahexaenoic acid and cholesterol. *J Lipid Res.* 1992 Aug;33(8):1147-56.
 7. Varma VK, Smith TK, Sorci-Thomas M, Ettinger WH Jr. Dexamethasone increases apolipoprotein A-I concentrations in medium and apolipoprotein A-I mRNA abundance from Hep G2 cells. *Metabolism.* 1992 Oct;41(10):1075-80.
 8. Colvin PL Jr, Wagner JD, Heuser MD, Sorci-Thomas MG. Oral contraceptives decrease hepatic cholesterol independent of the LDL receptor in nonhuman primates. *Arterioscler Thromb.* 1993 Nov;13(11):1645-9.
 9. Sorci-Thomas M, Kearns MW, Lee JP. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure: function relationships. *J Biol Chem.* 1993 Oct 05;268(28):21403-9.
 10. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, Verdery RB. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. *Arterioscler Thromb.* 1994 Jan;14(1):8-13.
 11. Shanker G, Sorci-Thomas M, Register TC, Adams MR. The inducible expression of THP-1 cell interleukin-1 mRNA: effects of estrogen on differential response to phorbol ester and lipopolysaccharide. *Lymphokine Cytokine Res.* 1994 Feb;13(1):1-7.
 12. Keiger CJ, O'Steen WK, Brewer G, Sorci-Thomas M, Zehnder TJ, Rose JC. Corticotropin releasing factor mRNA and peptide levels are differentially regulated in the developing ovine brain. *Brain Res Mol Brain Res.* 1994 Nov;27(1):103-10.
 13. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. *Lymphokine Cytokine Res.* 1994 Dec;13(6):377-82.
 14. Sorci-Thomas M, Kearns MW. Species-specific polymorphism in the promoter of the apolipoprotein A-I gene: restoration of human transcriptional efficiency by substitution at positions -189, -144 and -48 bp. *Biochim Biophys Acta.* 1995 Jun 06;1256(3):387-95.
 15. Keiger CJ, O'Steen WK, Brewer G, Sorci-Thomas M, Zehnder TJ, Rose JC. Cortisol up-regulates corticotropin releasing factor gene expression in the fetal ovine brainstem at 0.70 gestation. *Brain Res Mol Brain Res.* 1995 Aug;32(1):75-81.
 16. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the inducible expression of platelet-derived growth factor mRNA by monocyte/macrophages. *Life Sci.* 1995;56(7):499-507.
 17. Miller KR, Wang J, Sorci-Thomas M, Anderson RA, Parks JS. Glycosylation structure and enzyme activity of lecithin:cholesterol acyltransferase from human plasma, HepG2 cells, and baculoviral and Chinese hamster ovary cell expression systems. *J Lipid Res.* 1996 Mar;37(3):551-61.
 18. Sorci-Thomas MG, Parks JS, Kearns MW, Pate GN, Zhang C, Thomas MJ. High level secretion of wild-type and mutant forms of human proapoA-I using baculovirus-mediated Sf-9 cell expression. *J Lipid Res.* 1996 Mar;37(3):673-83.
 19. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. *J Biol Chem.* 1997 Mar 14;272(11):7278-84.
 20. Colvin PL Jr, Wagner JD, Adams MR, Sorci-Thomas MG. Sex steroids increase cholesterol 7alpha-hydroxylase mRNA in nonhuman primates. *Metabolism.* 1998 Apr;47(4):391-5.
 21. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW, Landrum M. The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin:cholesterol acyltransferase activation. *J Biol Chem.* 1998 May 08;273(19):11776-82.
 22. Sorci-Thomas MG, Thomas M, Curtiss L, Landrum M. Single repeat deletion in ApoA-I blocks cholesterol esterification and results in rapid catabolism of delta6 and wild-type ApoA-I in transgenic mice. *J Biol Chem.* 2000 Apr 21;275(16):12156-63.
 23. Li H, Lyles DS, Thomas MJ, Pan W, Sorci-Thomas MG. Structural determination of lipid-bound ApoA-I using fluorescence resonance energy transfer. *J Biol Chem.* 2000 Nov 24;275(47):37048-54.
 24. Thomas MJ, Chen Q, Zabalawi M, Anderson R, Wilson M, Weinberg R, Sorci-Thomas MG, Rudel LL. Is the oxidation of high-density lipoprotein lipids different than the oxidation of low-density lipoprotein lipids? *Biochemistry.* 2001 Feb 13;40(6):1719-24.
 25. Thomas MJ, Chen Q, Sorci-Thomas MG, Rudel LL. Isoprostane levels in lipids extracted from atherosclerotic arteries of nonhuman primates. *Free Radic Biol Med.* 2001 Jun 15;30(12):1337-46.

26. Li HH, Thomas MJ, Pan W, Alexander E, Samuel M, Sorci-Thomas MG. Preparation and incorporation of probe-labeled apoA-I for fluorescence resonance energy transfer studies of rHDL. *J Lipid Res.* 2001 Dec;42(12):2084-91.
27. Reschly EJ, Sorci-Thomas MG, Davidson WS, Meredith SC, Reardon CA, Getz GS. Apolipoprotein A-I alpha-helices 7 and 8 modulate high density lipoprotein subclass distribution. *J Biol Chem.* 2002 Mar 22;277(12):9645-54.
28. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. *Trends Cardiovasc Med.* 2002 Apr;12(3):121-8.
29. Li HH, Lyles DS, Pan W, Alexander E, Thomas MJ, Sorci-Thomas MG. ApoA-I structure on discs and spheres. Variable helix registry and conformational states. *J Biol Chem.* 2002 Oct 18;277(42):39093-101.
30. Schwenke DC, Rudel LL, Sorci-Thomas MG, Thomas MJ. Alpha-tocopherol protects against diet induced atherosclerosis in New Zealand white rabbits. *J Lipid Res.* 2002 Nov;43(11):1927-38.
31. Zabalawi M, Bhat S, Loughlin T, Thomas MJ, Alexander E, Cline M, Bullock B, Willingham M, Sorci-Thomas MG. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. *Am J Pathol.* 2003 Sep;163(3):1201-13. PMID: PMC1868257
32. Bhat S, Zabalawi M, Willingham MC, Shelness GS, Thomas MJ, Sorci-Thomas MG. Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions. *J Lipid Res.* 2004 Jul;45(7):1207-20.
33. Alexander ET, Bhat S, Thomas MJ, Weinberg RB, Cook VR, Bharadwaj MS, Sorci-Thomas M. Apolipoprotein A-I helix 6 negatively charged residues attenuate lecithin-cholesterol acyltransferase (LCAT) reactivity. *Biochemistry.* 2005 Apr 12;44(14):5409-19.
34. Bhat S, Sorci-Thomas MG, Alexander ET, Samuel MP, Thomas MJ. Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation: studies employing chemical cross-linking and mass spectrometry. *J Biol Chem.* 2005 Sep 23;280(38):33015-25.
35. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. *Circ Res.* 2005 Nov 25;97(11):1190-7. PMID: PMC1480357
36. Thomas MJ, Bhat S, Sorci-Thomas MG. The use of chemical cross-linking and mass spectrometry to elucidate the tertiary conformation of lipid-bound apolipoprotein A-I. *Curr Opin Lipidol.* 2006 Jun;17(3):214-20.
37. Zabalawi M, Bharadwaj M, Horton H, Cline M, Willingham M, Thomas MJ, Sorci-Thomas MG. Inflammation and skin cholesterol in LDLr^{-/-}, apoA-I^{-/-} mice: link between cholesterol homeostasis and self-tolerance? *J Lipid Res.* 2007 Jan;48(1):52-65.
38. Owen JS, Bharadwaj MS, Thomas MJ, Bhat S, Samuel MP, Sorci-Thomas MG. Ratio determination of plasma wild-type and L159R apoA-I using mass spectrometry: tools for studying apoA-I^{Fin}. *J Lipid Res.* 2007 Jan;48(1):226-34.
39. Bhat S, Sorci-Thomas MG, Tuladhar R, Samuel MP, Thomas MJ. Conformational adaptation of apolipoprotein A-I to discretely sized phospholipid complexes. *Biochemistry.* 2007 Jul 03;46(26):7811-21. PMID: PMC2553278
40. Thomas MJ, Bhat S, Sorci-Thomas MG. Three-dimensional models of HDL apoA-I: implications for its assembly and function. *J Lipid Res.* 2008 Sep;49(9):1875-83. PMID: PMC2515525
41. Sorci-Thomas MG, Bhat S, Thomas MJ. Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. *Clin Lipidol.* 2009 Feb;4(1):113-124. PMID: PMC2891274
42. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. *Arterioscler Thromb Vasc Biol.* 2009 Jun;29(6):843-9. PMID: PMC2761013
43. Bhat S, Sorci-Thomas MG, Calabresi L, Samuel MP, Thomas MJ. Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles. *Biochemistry.* 2010 Jun 29;49(25):5213-24. PMID: PMC2946800
44. Wang W, Xu H, Shi Y, Nandedkar S, Zhang H, Gao H, Feroah T, Weihrauch D, Schulte ML, Jones DW, Jarzembowski J, Sorci-Thomas M, Pritchard KA Jr. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. *J Lipid Res.* 2010 Sep;51(9):2560-70. PMID: PMC2918439

45. Wilhelm AJ, Zabalawi M, Owen JS, Shah D, Grayson JM, Major AS, Bhat S, Gibbs DP Jr, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr^{-/-}, ApoA-I^{-/-} mice. *J Biol Chem*. 2010 Nov 12;285(46):36158-69. PMID: PMC2975238
46. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of ApoE^{-/-} mice during disease regression. *J Clin Invest*. 2011 May;121(5):2025-36. PMID: PMC3083793
47. Sorci-Thomas MG, Zabalawi M, Bharadwaj MS, Wilhelm AJ, Owen JS, Asztalos BF, Bhat S, Thomas MJ. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice. *Biochim Biophys Acta*. 2012 Mar;1821(3):502-12. PMID: PMC3690280
48. Sorci-Thomas MG, Owen JS, Fulp B, Bhat S, Zhu X, Parks JS, Shah D, Jerome WG, Gerelus M, Zabalawi M, Thomas MJ. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. *J Lipid Res*. 2012 Sep;53(9):1890-909. PMID: PMC3413229
49. Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. *Arterioscler Thromb Vasc Biol*. 2012 Nov;32(11):2561-5. PMID: PMC3793253
50. Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M, Bittman R, Tall AR, Chen SH, Thomas MJ, Kreisel D, Swartz MA, Sorci-Thomas MG, Randolph GJ. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. *J Clin Invest*. 2013 Apr;123(4):1571-9. PMID: PMC3613904
51. Sorci-Thomas MG, Thomas MJ. Why targeting HDL should work as a therapeutic tool, but has not. *J Cardiovasc Pharmacol*. 2013 Sep;62(3):239-46. PMID: PMC3772973
52. Pollard RD, Fulp B, Samuel MP, Sorci-Thomas MG, Thomas MJ. The conformation of lipid-free human apolipoprotein A-I in solution. *Biochemistry*. 2013 Dec 31;52(52):9470-81. PMID: PMC3926756
53. Liu M, Seo J, Allegood J, Bi X, Zhu X, Boudyguina E, Gebre AK, Avni D, Shah D, Sorci-Thomas MG, Thomas MJ, Shelness GS, Spiegel S, Parks JS. Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. *J Biol Chem*. 2014 Jan 31;289(5):2801-14. PMID: PMC3908412
54. Gao M, Zhao D, Schouteden S, Sorci-Thomas MG, Van Veldhoven PP, Eggermont K, Liu G, Verfaillie CM, Feng Y. Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression. *Arterioscler Thromb Vasc Biol*. 2014 Sep;34(9):1900-9. PMID: PMC4140992
55. Tavori H, Su YR, Yancey PG, Giunzioni I, Wilhelm AJ, Blakemore JL, Zabalawi M, Linton MF, Sorci-Thomas MG, Fazio S. Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. *J Lipid Res*. 2015 Mar;56(3):635-643. PMID: PMC4340310
56. Chadwick AC, Holme RL, Chen Y, Thomas MJ, Sorci-Thomas MG, Silverstein RL, Pritchard KA Jr, Sahoo D. Acrolein impairs the cholesterol transport functions of high density lipoproteins. *PLoS One*. 2015;10(4):e0123138. PMID: PMC4388475
57. Pollard RD, Blesso CN, Zabalawi M, Fulp B, Gerelus M, Zhu X, Lyons EW, Nuradin N, Francone OL, Li XA, Sahoo D, Thomas MJ, Sorci-Thomas MG. Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) Reduces Atherosclerosis in Mice by Enhancing Scavenger Receptor Class B1 (SR-BI)-mediated High-density Lipoprotein (HDL)-Cholesteryl Ester Uptake. *J Biol Chem*. 2015 Jun 19;290(25):15496-15511. PMID: PMC4505464
58. Thomas MJ, Sorci-Thomas MG. SAA: a link between cholesterol efflux capacity and inflammation? *J Lipid Res*. 2015 Aug;56(8):1383-5. PMID: PMC4513981
59. Liu J, Lu H, Howatt DA, Balakrishnan A, Moorlegheh JJ, Sorci-Thomas M, Cassis LA, Daugherty A. Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. *Arterioscler Thromb Vasc Biol*. 2015 Aug;35(8):1826-34. PMID: PMC4514578
60. Navratil AR, Vozenilek AE, Cardelli JA, Green JM, Thomas MJ, Sorci-Thomas MG, Orr AW, Woolard MD. Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses. *Atherosclerosis*. 2015 Oct;242(2):424-32. PMID: PMC4712446
61. Sorci-Thomas MG, Pollard RD, Thomas MJ. What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport? *Curr Opin Lipidol*. 2015 Oct;26(5):420-5. PMID: PMC4564020
62. Sorci-Thomas MG, Thomas MJ. Microdomains, Inflammation, and Atherosclerosis. *Circ Res*. 2016 Feb 19;118(4):679-91. PMID: PMC5291489
63. Cheng HY, Gaddis DE, Wu R, McSkimming C, Haynes LD, Taylor AM, McNamara CA, Sorci-Thomas M, Hedrick CC. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. *J Clin*

- Invest. 2016 Sep 01;126(9):3236-46. PMID: PMC5004951
64. Pollard RD, Fulp B, Sorci-Thomas MG, Thomas MJ. High-Density Lipoprotein Biogenesis: Defining the Domains Involved in Human Apolipoprotein A-I Lipidation. *Biochemistry*. 2016 Sep 06;55(35):4971-81. PMID: PMC5356376
 65. Kaul S, Xu H, Zabalawi M, Maruko E, Fulp BE, Bluemn T, Brzoza-Lewis KL, Gerelus M, Weerasekera R, Kallinger R, James R, Zhang YS, Thomas MJ, Sorci-Thomas MG. Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio. *J Am Heart Assoc*. 2016 Nov 07;5(11). PMID: PMC5210328
 66. Lee MH, Appleton KM, El-Shewy HM, Sorci-Thomas MG, Thomas MJ, Lopes-Virella MF, Luttrell LM, Hammad SM, Klein RL. S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization. *J Lipid Res*. 2017 Feb;58(2):325-338. PMID: PMC5282949
 67. Hoekstra M, Sorci-Thomas M. Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor. *Curr Opin Lipidol*. 2017 Jun;28(3):255-260. PMID: PMC5523812
 68. Sorci-Thomas MG, Thomas MJ. AIBP, NAXE, and Angiogenesis: What's in a Name? *Circ Res*. 2017 May 26;120(11):1690-1691. PMID: PMC5497770
 69. Sorci-Thomas MG, Thomas MJ. Anti-inflammatory liaisons: T regulatory cells and HDL. *J Lipid Res*. 2017 Aug;58(8):1491-1492. PMID: PMC5538272
 70. Williams JW, Elvington A, Ivanov S, Kessler S, Luehmann H, Baba O, Saunders BT, Kim KW, Johnson MW, Craft CS, Choi JH, Sorci-Thomas MG, Zinselmeyer BH, Brestoff JR, Liu Y, Randolph GJ. Thermoneutrality but Not UCP1 Deficiency Suppresses Monocyte Mobilization Into Blood. *Circ Res*. 2017 Sep 01;121(6):662-676. PMID: PMC5718914
 71. Melchior JT, Walker RG, Cooke AL, Morris J, Castleberry M, Thompson TB, Jones MK, Song HD, Rye KA, Oda MN, Sorci-Thomas MG, Thomas MJ, Heinecke JW, Mei X, Atkinson D, Segrest JP, Lund-Katz S, Phillips MC, Davidson WS. A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state. *Nat Struct Mol Biol*. 2017 Dec;24(12):1093-1099. PMID: PMC5749415
 72. Milasan A, Jean G, Dallaire F, Tardif JC, Merhi Y, Sorci-Thomas M, Martel C. Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice. *J Am Heart Assoc*. 2017 Sep 22;6(9). PMID: PMC5634311
 73. Favari E, Thomas MJ, Sorci-Thomas MG. High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis. *J Cardiovasc Pharmacol*. 2018 Jun;71(6):325-331.
 74. Gaddis DE, Padgett LE, Wu R, McSkimming C, Romines V, Taylor AM, McNamara CA, Kronenberg M, Crotty S, Thomas MJ, Sorci-Thomas MG, Hedrick CC. Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. *Nat Commun*. 2018 Mar 15;9(1):1095. PMID: PMC5854619
 75. Huang LH, Zinselmeyer BH, Chang CH, Saunders BT, Elvington A, Baba O, Broekelmann TJ, Qi L, Rueve JS, Swartz MA, Kim BS, Mechem RP, Wiig H, Thomas MJ, Sorci-Thomas MG, Randolph GJ. Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis. *Cell Metab*. 2019 Feb 05;29(2):475-487.e7. PMID: PMC6365189
 76. Ossoli A, Simonelli S, Varrenti M, Morici N, Oliva F, Stucchi M, Gomaschi M, Strazzella A, Arnaboldi L, Thomas MJ, Sorci-Thomas MG, Corsini A, Veglia F, Franceschini G, Karathanasis SK, Calabresi L. Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome. *Arterioscler Thromb Vasc Biol*. 2019 May;39(5):915-924.
 77. Rodriguez A, Trigatti BL, Mineo C, Knaack D, Wilkins JT, Sahoo D, Asztalos BF, Mora S, Cuchel M, Pownall HJ, Rosales C, Bernatchez P, Ribeiro Martins da Silva A, Getz GS, Barber JL, Shearer GC, Zivkovic AM, Tietge UJF, Sacks FM, Connelly MA, Oda MN, Davidson WS, Sorci-Thomas MG, Vaisar T, Ruotolo G, Vickers KC, Martel C. Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. *Arterioscler Thromb Vasc Biol*. 2019 Dec;39(12):2457-2467. PMID: PMC6937204
 78. Ouweneel AB, Thomas MJ, Sorci-Thomas MG. The ins and outs of lipid rafts: functions in intracellular cholesterol homeostasis, microparticles, and cell membranes. *J Lipid Res*. 2020 05;61(5):676-686. PMID: PMC7193959
 79. Li Z, Votava JA, Zajac GJM, Nguyen JN, Leyva Jaimes FB, Ly SM, Brinkman JA, De Giorgi M, Kaul S,

- Green CL, St Clair SL, Belisle SL, Rios JM, Nelson DW, Sorci-Thomas MG, Lagor WR, Lamming DW, Eric Yen CL, Parks BW. Integrating Mouse and Human Genetic Data to Move beyond GWAS and Identify Causal Genes in Cholesterol Metabolism. *Cell Metab.* 2020 Apr 07;31(4):741-754.e5. PMID: PMC7184639
80. Thomas MJ, Sorci-Thomas MG. Linking Lipid-Related Transcription and Cardiovascular Disease Through GWAS. *Circ Res.* 2020 Nov 06;127(11):1362-1364. PMID: PMC7653958
81. Singh B, Kosuru R, Lakshmikanthan S, Sorci-Thomas MG, Zhang DX, Sparapani R, Vasquez-Vivar J, Chrzanoswska M. Endothelial Rap1 (Ras-Association Proximate 1) Restricts Inflammatory Signaling to Protect From the Progression of Atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2021 Feb;41(2):638-650. PMID: PMC8105264
82. Ouweneel AB, Thomas MJ, Sorci-Thomas MG. The ins and outs of lipid rafts: functions in intracellular cholesterol homeostasis, microparticles, and cell membranes: Thematic Review Series: Biology of Lipid Rafts. *J Lipid Res.* 2020 May;61(5):676-686. PMID: PMC7193959
83. Han YH, Onufer EJ, Huang LH, Sprung RW, Davidson WS, Czepliewski RS, Wohltmann M, Sorci-Thomas MG, Warner BW, Randolph GJ. Enterically derived high-density lipoprotein restrains liver injury through the portal vein *Science.* 23 July 2021;373(6553).
84. Neu SD, Strzepa A, Martin D, Sorci-Thomas MG, Pritchard KA, Dittel BN. Myeloperoxidase inhibition ameliorates plaque psoriasis in mice *Antioxidants.* September 2021;10(9).
85. Han YH, Onufer EJ, Huang LH, Sprung RW, Davidson WS, Czepliewski RS, Wohltmann M, Sorci-Thomas MG, Warner BW, Randolph GJ. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. *Science.* 2021 Jul 23;373(6553). PMID: PMC8478306
86. Hafiane A, Gianopoulos I, Sorci-Thomas MG, Daskalopoulou SS. Current models of apolipoprotein A-I lipidation by adenosine triphosphate binding cassette transporter A1. *Curr Opin Lipidol.* 2022 Apr 01;33(2):139-145.
87. Neu SD, Strzepa A, Martin D, Sorci-Thomas MG, Pritchard KA Jr, Dittel BN. Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice. *Antioxidants (Basel).* 2021 Aug 25;10(9). PMID: PMC8472607
88. Xu H, Thomas MJ, Kaul S, Kallinger R, Ouweneel AB, Maruko E, Oussaada SM, Jongejan A, Cense HA, Nieuwdorp M, Serlie MJ, Goldberg IJ, Civelek M, Parks BW, Lusic AJ, Knaack D, Schill RL, May SC, Reho JJ, Grobe JL, Gantner B, Sahoo D, Sorci-Thomas MG. Pcp2, a Novel Extracellular Matrix Protein, Regulates Adipocyte SR-BI-Mediated High-Density Lipoprotein Uptake. *Arterioscler Thromb Vasc Biol.* 2021 Nov;41(11):2708-2725. PMID: PMC8551036
89. Hafiane A, Gianopoulos I, Sorci-Thomas MG, Daskalopoulou SS. Apolipoprotein A-I carboxy-terminal domain residues 187-243 are required for adiponectin-induced cholesterol efflux. *Cell Signal.* 2022 Mar;91:110222.
90. Vachon L, Smaani A, Tessier N, Jean G, Demers A, Milasan A, Ardo N, Jarry S, Villeneuve L, Alikashani A, Finherty V, Ruiz M, Sorci-Thomas MG, Mayer G, Martel C. Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids *Theranostics.* 2022;12(3):1440-1458.
91. Vachon L, Smaani A, Tessier N, Jean G, Demers A, Milasan A, Ardo N, Jarry S, Villeneuve L, Alikashani A, Finherty V, Ruiz M, Sorci-Thomas MG, Mayer G, Martel C. Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids. *Theranostics.* 2022;12(3):1440-1458. PMID: PMC8771568
92. Knaack DA, Sorci-Thomas MG, Thomas MJ, Chen Y, Sahoo D. Regulation of Adipocyte Metabolic Homeostasis by SR-BI and PCPE2. *FASEB J.* 2022 May;36 Suppl 1.
93. Natarajan R, Moore K, Sahoo D, Nana-Sinkam P, Fowler AAB 3rd, Sime P, Sorci-Thomas M, Aikawa E, ATVB Council, friends, and colleagues. Shobha Ghosh (1958-2021). *Arterioscler Thromb Vasc Biol.* 2022 Mar;42(3):239-240.
94. Wacker BK, Bi L, Liu L, Sorci-Thomas MG, Ng P, Palmer DJ, Tang C, Dichek DA. N-terminal eGFP-tagging of rabbit apolipoprotein A-I decreases expression and impairs cholesterol-efflux activity. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2023 May;1868(5):159301. PMID: PMC10127936
95. Schmidt AM, Sorci-Thomas MG, Chen Y, Hegele RA. Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies. *Arterioscler Thromb Vasc Biol.* 2023 Jul;43(7):1093-1095. PMID: PMC10330751
96. Mo ZW, Peng YM, Zhang YX, Li Y, Kang BA, Chen YT, Li L, Sorci-Thomas MG, Lin YJ, Cao Y, Chen S, Liu ZL, Gao JJ, Huang ZP, Zhou JG, Wang M, Chang GQ, Deng MJ, Liu YJ, Ma ZS, Hu ZJ, Dong YG, Ou ZJ, Ou JS. High-density lipoprotein regulates angiogenesis by long non-coding RNA

- HDRACA. *Signal Transduct Target Ther*. 2023 Aug 14;8(1):299. PMID: PMC10423722
97. Dai W, Zhang H, Lund H, Zhang Z, Castleberry M, Rodriguez M, Kuriakose G, Gupta S, Lewandowska M, Powers HR, Valmiki S, Zhu J, Shapiro AD, Hussain MM, López JA, Sorci-Thomas MG, Silverstein RL, Ginsberg HN, Sahoo D, Tabas I, Zheng Z. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes. *Science*. 2023 Sep;381(6661):eadh5207. PMID: PMC10697821
 98. Knaack DA, Chang J, Thomas MJ, Sorci-Thomas MG, Chen Y, Sahoo D. Scavenger receptor class B type I is required for efficient glucose uptake and metabolic homeostasis in adipocytes. *bioRxiv*. 2023 Aug 22. PMID: PMC10473602
 99. Nagesh PT, Nishi H, Rawal S, Zahr T, Miano JM, Sorci-Thomas M, Xu H, Akbar N, Choudhury RP, Misra A, Fisher EA. HDL regulates TGF β -receptor lipid raft partitioning, restoring contractile features of cholesterol-loaded vascular smooth muscle cells. *bioRxiv*. 2023 Oct 19. PMID: PMC10614922
 100. Sorci-Thomas MG, Hegele RA, Remaley AT. A Century of Milestones and Breakthroughs Related to Low- and High-Density Lipoproteins. *Arterioscler Thromb Vasc Biol*. 2024 Jan;44(1):7-11. PMID: PMC10760802
 101. Aikawa E, Allison MA, Iruela Arispe L, Bendeck MP, Chen Y, Gardiner EE, Golledge J, Suzuki-Inoue K, Marelli-Berg F, Powell JT, Ramasamy R, Sarpong DF, Sorci-Thomas MG, Daugherty A, Hegele RA, Schmidt AM. Honoring the Life and Legacy of Dr David A. Dichek. *Arterioscler Thromb Vasc Biol*. 2024 Jul;44(7):1459-1461.
 102. Thomas MJ, Xu H, Wang A, Beg MA, Sorci-Thomas MG. PCPE2: Expression of multifunctional extracellular glycoprotein associated with diverse cellular functions. *J Lipid Res*. 2024 Nov;65(11):100664. PMID: PMC11567036
 103. Liu Z, Cao Y, Liao XL, Ou ZJ, Mo ZW, Liu YF, Chen YT, Liu ZL, Gao JJ, Ning DS, Peng YM, Sorci-Thomas MG, Ou JS, Li Y. Apolipoprotein A-I Mimetic Peptide Restores VEGF-induced Angiogenesis in Hypercholesterolemic Ischemic Heart by Reducing HDL Proinflammatory Properties. *J Cardiovasc Transl Res*. 2025 Feb;18(1):58-69. PMID: PMC11885385
 104. Aikawa E, Allison MA, Iruela Arispe L, Bendeck MP, Chen Y, Gardiner EE, Golledge J, Suzuki-Inoue K, Marelli-Berg F, Powell JT, Ramasamy R, Sarpong DF, Sorci-Thomas MG, Daugherty A, Hegele RA, Schmidt AM. Honoring the Life and Legacy of Dr David A. Dichek. *Arterioscler Thromb Vasc Biol*. 2024 Jul;44(7):1459-1461.
 105. Nagesh PT, Rawal S, Nishi H, Zahr T, Miano JM, Sorci-Thomas M, Xu H, Akbar N, Choudhury RP, Feinberg MW, Misra A, Fisher EA. HDL Regulates TGF β -Receptor Lipid Raft Partitioning, Restoring Contractile Features of Cholesterol-Loaded Vascular Smooth Muscle Cells. *JACC Basic Transl Sci*. 2026 Mar;11(3):101461. PMID: PMC12925216
 106. Sorci-Thomas MG, Rocksvold A, Ahmad B. PCPE1 and PCPE2: When Sequence Similarity Masks Functional Diversity. *Arterioscler Thromb Vasc Biol*. 2026 Jun;46(6):e324421.